VARIABLE ORAL ABSORPTION OF CYCLOSPORINE
- 1 September 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 62 (5), 599-606
- https://doi.org/10.1097/00007890-199609150-00010
Abstract
The inter- and intrapatient variability in cyclosporine (CsA) pharmacokinetics obfuscates the relationship between therapeutic outcome and administered dose, thereby impeding the development of secure algorithms for CsA therapy. In an attempt to understand these variabilities, we previously performed serial pharmacokinetic profiles on 160 renal transplant recipients during the first 3 posttransplant months. Drug exposure was estimated by the average CsA concentration (Cav), which was defined as a time-corrected (tau, hours) expression of the area under the concentration-time curve (AUC), i.e., Cav = (AUC/tau). Low Cav values correlated with an increased occurrence of acute rejection episodes and 1-year rate of renal transplant loss. The present study examines the results of serial pharmacokinetic profiling of a cohort of 204 patients treated for up to 5 years with CsA doses selected to achieve target Cav values. Multivariate analyses correlated demographic factors, laboratory values, clinical parameters, and CsA pharmacokinetic parameters with the occurrence of chronic rejection. The factors that predisposed to chronic rejection included a previous acute rejection episode, initial acute tubular necrosis, diastolic blood pressure above 85 mmHg, and African-American race. Once regression models were adjusted to account for the impact of these factors, we examined the association between the incidence of chronic rejection and individual pharmacokinetic parameters, including the mean values of the absolute and dose-corrected trough, peak, and Cav concentrations, as well as the percent coefficient of variation of each of these values. Receiver operating characteristic curves documented that 27% of the total risk for the occurrence of chronic rejection was attributable to a greater than 20% coefficient of variation of the dose-corrected Cav, namely, AUC/(tau.mg). This study suggests that variable oral bioavailability of CsA represents a biopharmaceutical risk factor for the occurrence of chronic rejection.Keywords
This publication has 22 references indexed in Scilit:
- REVERSIBILITY OF CHRONIC RENAL ALLOGRAFT REJECTIONTransplantation, 1994
- Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantationClinical Pharmacology & Therapeutics, 1993
- Nephron Underdosing: A Programmed Cause of Chronic Renal Allograft FailureAmerican Journal of Kidney Diseases, 1993
- Chronic transplant rejection: Magnitude of the problem and pathogenetic mechanismsTransplantation Reviews, 1993
- LRISK FACTORS FOR CHRONIC REJECTION IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1993
- Specific Monoclonal Radioimmunoassay and Fluorescence Polarization Immunoassay for Trough Concentration and Area-Under-the-Curve Monitoring of Cyclosporine in Renal TransplantationTherapeutic Drug Monitoring, 1992
- CyclosporineNew England Journal of Medicine, 1989
- THE RELATIONSHIP BETWEEN CYCLOSPORINE PHARMACOKINETIC PARAMETERS AND SUBSEQUENT ACUTE REJECTION IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1988
- MULTIVARIATE ANALYSIS OF RISK FACTORS IMPACTING ON IMMEDIATE AND EVENTUAL CADAVER ALLOGRAFT SURVIVAL IN CYCLOSPORINE-TREATED RECIPIENTSTransplantation, 1987
- Noncompartmental Determination of the Steady‐State Volume of DistributionJournal of Pharmaceutical Sciences, 1979